Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553991 | 0.94 | OPRD1 (0.54) | OPRD1KDM4EUSP2TMEM97SIGMAR1 | |
| SCHEMBL6550223 | 0.86 | KMT2A (0.51) | OPRD1TMEM97SIGMAR1KMT2ANPC1 | |
| SCHEMBL23610369 | 0.81 | KDM4E (0.71) | KDM4EUSP2KMT2ANPC1RAB9A | |
| SCHEMBL17737082 | 0.81 | KDM4E (0.71) | KDM4EUSP2KMT2ANPC1RAB9A | |
| SCHEMBL175992 | 0.80 | CHRNA7 (0.58) | OPRD1KDM4EUSP2SIGMAR1 | |
| SCHEMBL1742053 | 0.80 | CHRNB2 (0.57) | OPRD1KDM4EUSP2KMT2ANPC1 | |
| SCHEMBL1305549 | 0.79 | CHRNA7 (0.62) | KDM4EUSP2KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL4653256 | 0.78 | CHRNA7 (0.61) | KDM4EUSP2KMT2ANPC1RAB9A | |
| SCHEMBL63379 | 0.78 | KDM4E (0.54) | KDM4EUSP2KMT2AENPP2CHEK1 | |
| SCHEMBL7423220 | 0.78 | OPRD1 (0.60) | OPRD1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996031476-A1 | AROMATIC HYDROXYETHERS | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | claimed |
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| US-20150191459-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2015-07-09 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| EP-2078009-B1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| EP-0960096-A1 | SUBSTITUTED $g(b)-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999033789-A1 | SUBSTITUTED β-ALANINES | AVENTIS PHARMA LIMITED (GB) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999023063-A1 | SUBSTITUTED ANILIDES | AVENTIS PHARMA LIMITED (GB) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998032734-A1 | SUBSTITUTED β-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997003967-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | RHONE-POULENC RORER LIMITED (GB) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996031476-A1 | AROMATIC HYDROXYETHERS | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | OPRD1 776/4885KDM4E 3577/4885USP2 1365/4885 |
| US-20150191459-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | OPRD1 4175/4885KDM4E 2762/4885USP2 302/4885 |
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | OPRD1 382/4885KDM4E 277/4885USP2 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.